Ptc Therapeutics (PTCT) Cost of Revenue (2017 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Cost of Revenue of $19.9 million for Q2 2026, up 74.44% year-over-year from $11.4 million in Q2 2025, and down 28.92% quarter-over-quarter from $28.0 million in Q1 2026.
Ptc Therapeutics (PTCT) Cost of Revenue (2017 - 2026) Analysis & Trends
Ptc Therapeutics' Cost of Revenue history runs 10 years deep, the most recent figure standing at $19.9 million for Q2 2026.
- In Q2 2026, Cost of Revenue rose 74.44% year-over-year to $19.9 million; the TTM figure through Jun 2026 stood at $70.7 million (up 37.47% YoY), while the FY2025 annual figure was $47.0 million, down 18.09% from the prior year.
- Cost of Revenue for Q2 2026 stood at $19.9 million, down from $28.0 million in the prior quarter.
- The five-year high for Cost of Revenue was $29.1 million in Q4 2023, with the low at $7.0 million in Q4 2025.
- The 5-year median for Cost of Revenue is $13.4 million (2022), against an average of $14.6 million.
- The sharpest annual moves came in 2023 and 2025: Cost of Revenue soared 167.31% in 2023, then tumbled 57.32% in 2025.
- Ptc Therapeutics' Cost of Revenue stood at $10.9 million in 2022, then surged by 167.31% to $29.1 million in 2023, then plunged by 44.08% to $16.3 million in 2024, then sank by 57.32% to $7.0 million in 2025, then surged by 186.63% to $19.9 million in 2026.
- Business Quant data shows PTCT's Cost of Revenue at $19.9 million in Q2 2026, $28.0 million in Q1 2026, and $7.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 19.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.92 Mn |
| Jun 30, 2026 | 19.92 Mn |
| Mar 31, 2026 | 28.03 Mn |
| Mar 31, 2026 | 28.03 Mn |
| Dec 31, 2025 | 6.95 Mn |
| Dec 31, 2025 | 6.95 Mn |
| Sep 30, 2025 | 15.78 Mn |
| Sep 30, 2025 | 15.78 Mn |
| Jun 30, 2025 | 11.42 Mn |
| Jun 30, 2025 | 11.42 Mn |
| Mar 31, 2025 | 12.86 Mn |
| Mar 31, 2025 | 12.86 Mn |
| Dec 31, 2024 | 16.28 Mn |
| Dec 31, 2024 | 16.28 Mn |
| Sep 30, 2024 | 10.85 Mn |
| Sep 30, 2024 | 10.85 Mn |
| Jun 30, 2024 | 15.53 Mn |
| Jun 30, 2024 | 15.53 Mn |
| Mar 31, 2024 | 14.74 Mn |
| Mar 31, 2024 | 14.74 Mn |